C

L

CHAIGNEAU , Loic

Last name: CHAIGNEAU

First name: Loic

December 2014 (v1)

Journal article

Metadata-only

The off-label use of targeted therapies in sarcomas: the OUTC'S program

Eberst, Lauriane Cropet, Claire Le Cesne, Axel

Background: Few targeted therapies (TTs) are registered for sarcoma treatment despite numerous phase II studies and yet there are potential treatment options for patients after standard treatment escape. The French Sarcoma Group - Bone Tumor Study Group (GSF-GETO) created a national registry to evaluate the outcome of patients treated with...

Uploaded on: December 3, 2022
June 2021 (v1)

Journal article

Metadata-only

Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study

Duffaud, Florence Italiano, Antoine Bompas, Emannuelle

International audience

Uploaded on: December 3, 2022
2017 (v1)

Journal article

Metadata-only

New advances in DPYD genotype and risk of severe toxicity under capecitabine

Etienne-Grimaldi, Marie-Christine Boyer, Christophe Béroud, Christophe

Background: Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping and phenotyping. The goal of this prospective observational study was to perform exhaustive exome DPYD...

Uploaded on: December 4, 2022